The Cost-Effectiveness of Neonatal versus Prenatal Screening for Congenital Toxoplasmosis

Authors

Christine Binquet, Universitaire Dijon-Bourgogne
Catherine Lejeune, Universitaire Dijon-Bourgogne
Valérie Seror, Universite d'Aix-Marseille III
François Peyron, Institut de Parasitologie et de Mycologie Médicale
Anne-Claire Bertaux, Universitaire Dijon-Bourgogne
Olivier Scemama, Haute Autorité de Santé
Catherine Quantin, Universitaire Dijon-Bourgogne
Sophie Béjean, Université de Bourgogne
Eileen Stillwaggon, Gettysburg CollegeFollow
Martine Wallon, Institut de Parasitologie et de Mycologie Médicale

Document Type

Article

Publication Date

9-18-2019

Department 1

Economics

Abstract

Congenital Toxoplasmosis (CT) can have severe consequences. France, Austria, and Slovenia have prenatal screening programs whereas some other countries are considering universal screening to reduce congenital transmission and severity of infection in children. The efficiency of such programs is debated increasingly as seroprevalence among pregnant women and incidence of congenital toxoplasmosis show a steady decrease. In addition, uncertainty remains regarding the effectiveness of pre- and postnatal treatments.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

DOI

10.1371/journal.pone.0221709

Version

Version of Record

Recommended Citation

Binquet, C., Lejeune, C., Seror, V., Peyron, F., Bertaux, A.C., Scemama, O., Quantin, C., Béjean, S., Stillwaggon, E., Wallon, M. (2019.) The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis. PLoS ONE 14(9): e0221709.

Required Publisher's Statement

This article was originally published on the publisher's website: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221709